;PMID: 8631189
;source_file_2665.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..35] = [t:0..35]
;1)sentence:[e:41..105] = [t:41..105]
;2)section:[e:109..180] = [t:109..180]
;3)section:[e:184..269] = [t:184..269]
;4)sentence:[e:273..444] = [t:273..444]
;5)sentence:[e:445..645] = [t:445..645]
;6)sentence:[e:646..935] = [t:646..935]
;7)sentence:[e:936..1017] = [t:936..1017]
;8)sentence:[e:1018..1113] = [t:1018..1113]
;9)sentence:[e:1114..1273] = [t:1114..1273]
;10)section:[e:1277..1295] = [t:1277..1295]
;11)section:[e:1301..1315] = [t:1301..1315]
;12)section:[e:1321..1348] = [t:1321..1348]
;13)section:[e:1352..1396] = [t:1352..1396]

;section 0 Span:0..35
;Contraception. 1996 Jan;53(1):41-7.
(SEC
  (FRAG (NN:[0..13] Contraception) (RB:[13..14] .) (CD:[15..19] 1996)
        (IN:[20..26] Jan;53) (-LRB-:[26..27] -LRB-) (CD:[27..28] 1)
        (-RRB-:[28..29] -RRB-) (::[29..30] :) (CD:[30..32] 41) (HYPH:[32..33] -)
        (CD:[33..35] 7.)))

;sentence 1 Span:41..105
;Can grapefruit juice influence ethinylestradiol bioavailability?
;[45..61]:substance:"grapefruit juice"
;[72..88]:substance:"ethinylestradiol"
(SENT
  (SQ-HLN (MD:[41..44] Can)
    (NP-SBJ (NN:[45..55] grapefruit) (NN:[56..61] juice))
    (VP (VB:[62..71] influence)
      (NP (NN:[72..88] ethinylestradiol) (NN:[89..104] bioavailability)))
    (.:[104..105] ?)))

;section 2 Span:109..180
;Weber A, Jager R, Borner A, Klinger G, Vollanth R, Matthey K, Balogh A.
(SEC
  (FRAG (NNP:[109..114] Weber) (NNP:[115..116] A) (,:[116..117] ,)
        (NNP:[118..123] Jager) (NNP:[124..125] R) (,:[125..126] ,)
        (NNP:[127..133] Borner) (NNP:[134..135] A) (,:[135..136] ,)
        (NNP:[137..144] Klinger) (NNP:[145..146] G) (,:[146..147] ,)
        (NNP:[148..156] Vollanth) (NNP:[157..158] R) (,:[158..159] ,)
        (NNP:[160..167] Matthey) (NNP:[168..170] K,) (NNP:[171..177] Balogh)
        (NNP:[178..179] A) (.:[179..180] .)))

;section 3 Span:184..269
;Department of Clinical Pharmacology, Friedrich Schiller University of Jena, 
;Germany.
(SEC
  (FRAG (NNP:[184..194] Department) (IN:[195..197] of) (NNP:[198..206] Clinical)
        (NNP:[207..219] Pharmacology) (,:[219..220] ,)
        (NNP:[221..230] Friedrich) (NNP:[231..239] Schiller)
        (NNP:[240..250] University) (IN:[251..253] of) (NNP:[254..258] Jena)
        (,:[258..259] ,) (NNP:[261..268] Germany) (.:[268..269] .)))

;sentence 4 Span:273..444
;The effects of grapefruit juice on the bioavailability of 17 
;alpha-ethinylestradiol (EE2) after a single oral administration of 50
;micrograms  EE2 have been investigated.
;[288..304]:substance:"grapefruit juice"
;[331..357]:substance:"17  alpha-ethinylestradiol"
;[359..362]:substance:"EE2"
;[402..404]:quantitative-value:"50"
;[405..415]:quantitative-units:"micrograms"
;[417..420]:substance:"EE2"
(SENT
  (S
    (NP-SBJ-1
      (NP
        (NP (DT:[273..276] The) (NNS:[277..284] effects))
        (PP (IN:[285..287] of)
          (NP (NN:[288..298] grapefruit) (NN:[299..304] juice)))
        (PP (IN:[305..307] on)
          (NP
            (NP (DT:[308..311] the) (NN:[312..327] bioavailability))
            (PP (IN:[328..330] of)
              (NP
                (NP (CD:[331..333] 17) (NN:[335..357] alpha-ethinylestradiol))
                (NP (-LRB-:[358..359] -LRB-) (NN:[359..362] EE2)
                    (-RRB-:[362..363] -RRB-)))))))
      (PP (IN:[364..369] after)
        (NP
          (NP (DT:[370..371] a) (JJ:[372..378] single) (JJ:[379..383] oral)
              (NN:[384..398] administration))
          (PP (IN:[399..401] of)
            (NP
              (NML (CD:[402..404] 50) (NNS:[405..415] micrograms))
              (NN:[417..420] EE2))))))
    (VP (VBP:[421..425] have)
      (VP (VBN:[426..430] been)
        (VP (VBN:[431..443] investigated)
          (NP-1 (-NONE-:[443..443] *)))))
    (.:[443..444] .)))

;sentence 5 Span:445..645
;The pharmacokinetics of EE2 were studied in an open,  randomized, cross-over
;study in which 13 healthy volunteers were administered  the drug with herbal
;tea or grapefruit juice (naringin, 887 mg/ml).
;[469..472]:substance:"EE2"
;[582..586]:substance:"drug"
;[592..602]:substance:"herbal tea"
;[606..622]:substance:"grapefruit juice"
;[624..632]:substance:"naringin"
;[634..637]:quantitative-value:"887"
;[638..643]:quantitative-units:"mg/ml"
(SENT
  (S
    (NP-SBJ-2
      (NP (DT:[445..448] The) (NNS:[449..465] pharmacokinetics))
      (PP (IN:[466..468] of)
        (NP (NN:[469..472] EE2))))
    (VP (VBD:[473..477] were)
      (VP (VBN:[478..485] studied)
        (NP-2 (-NONE-:[485..485] *))
        (PP-LOC (IN:[486..488] in)
          (NP
            (NP (DT:[489..491] an) (JJ:[492..496] open) (,:[496..497] ,)
                (VBN:[499..509] randomized) (,:[509..510] ,)
              (ADJP (VB:[511..516] cross) (HYPH:[516..517] -)
                    (RP:[517..521] over))
              (NN:[522..527] study))
            (SBAR
              (WHPP-3 (IN:[528..530] in)
                (WHNP (WDT:[531..536] which)))
              (S
                (NP-SBJ-1 (CD:[537..539] 13) (JJ:[540..547] healthy)
                          (NNS:[548..558] volunteers))
                (VP (VBD:[559..563] were)
                  (VP (VBN:[564..576] administered)
                    (NP-1 (-NONE-:[576..576] *))
                    (NP (DT:[578..581] the) (NN:[582..586] drug))
                    (PP (IN:[587..591] with)
                      (NP
                        (NP (JJ:[592..598] herbal) (NN:[599..602] tea))
                        (CC:[603..605] or)
                        (NP
                          (NP (NN:[606..616] grapefruit) (NN:[617..622] juice))
                          (PRN (-LRB-:[623..624] -LRB-)
                            (FRAG
                              (NP (NN:[624..632] naringin))
                              (,:[632..633] ,)
                              (NP
                                (NP (CD:[634..637] 887) (NN:[638..640] mg))
                                (PP (SYM:[640..641] /)
                                  (NP (NN:[641..643] ml)))))
                            (-RRB-:[643..644] -RRB-)))))
                    (PP-3 (-NONE-:[644..644] *T*))))))))))
    (.:[644..645] .)))

;sentence 6 Span:646..935
;In contrast  to herbal tea, grapefruit juice increased the peak plasma
;concentration (Cmax)  significantly to 137% (mean; range 64% to 214%, p =
;0.0088) and increased the  area under plasma concentration-time curve from 0
;to 8 hours (AUC0-8) to 128%  (mean; range 81% to 180%, p = 0.0186).
;[662..672]:substance:"herbal tea"
;[674..690]:substance:"grapefruit juice"
;[732..736]:quantitative-name:"Cmax"
;[756..760]:quantitative-value:"137%"
;[861..872]:quantitative-value:"from 0 to 8"
;[873..878]:quantitative-units:"hours"
;[891..895]:quantitative-value:"128%"
;[910..921]:quantitative-value:"81% to 180%"
(SENT
  (S
    (PP (IN:[646..648] In)
      (NP
        (NP (NN:[649..657] contrast))
        (PP (TO:[659..661] to)
          (NP (JJ:[662..668] herbal) (NN:[669..672] tea)))))
    (,:[672..673] ,)
    (NP-SBJ (NN:[674..684] grapefruit) (NN:[685..690] juice))
    (VP
      (VP (VBD:[691..700] increased)
        (NP
          (NP (DT:[701..704] the) (JJ:[705..709] peak) (NN:[710..716] plasma)
              (NN:[717..730] concentration))
          (PRN (-LRB-:[731..732] -LRB-)
            (NP (NN:[732..736] Cmax))
            (-RRB-:[736..737] -RRB-)))
        (ADVP (RB:[739..752] significantly))
        (PP (TO:[753..755] to)
          (NP (CD:[756..759] 137) (NN:[759..760] %)))
        (PRN (-LRB-:[761..762] -LRB-)
          (NP (NN:[762..766] mean))
          (::[766..767] ;)
          (FRAG
            (FRAG
              (NP-SBJ (NN:[768..773] range))
              (NP-PRD
                (NP (CD:[774..776] 64) (NN:[776..777] %))
                (PP (TO:[778..780] to)
                  (NP (CD:[781..784] 214) (NN:[784..785] %)))))
            (,:[785..786] ,)
            (S
              (NP-SBJ (NN:[787..788] p))
              (VP (SYM:[789..790] =)
                (NP (CD:[791..797] 0.0088)))))
          (-RRB-:[797..798] -RRB-)))
      (CC:[799..802] and)
      (VP (VBD:[803..812] increased)
        (NP
          (NP (DT:[813..816] the) (NN:[818..822] area))
          (PP (IN:[823..828] under)
            (NP
              (NML
                (NML (NN:[829..835] plasma) (NN:[836..849] concentration))
                (HYPH:[849..850] -)
                (NML (NN:[850..854] time)))
              (NN:[855..860] curve)))
          (PP (IN:[861..865] from)
            (NP (CD:[866..867] 0)
              (NML-1 (-NONE-:[867..867] *RNR*))))
          (PP (TO:[868..870] to)
            (NP (CD:[871..872] 8)
              (NML-1 (-NONE-:[872..872] *RNR*))))
          (NML-1 (NNS:[873..878] hours))
          (PRN (-LRB-:[879..880] -LRB-)
            (NP (NN:[880..883] AUC) (CD:[883..884] 0) (HYPH:[884..885] -)
                (CD:[885..886] 8))
            (-RRB-:[886..887] -RRB-)))
        (PP (TO:[888..890] to)
          (NP (CD:[891..894] 128) (NN:[894..895] %)))
        (PRN (-LRB-:[897..898] -LRB-)
          (NP (NN:[898..902] mean))
          (::[902..903] ;)
          (FRAG
            (FRAG
              (NP-SBJ (NN:[904..909] range))
              (NP-PRD
                (NP (CD:[910..912] 81) (NN:[912..913] %))
                (PP (TO:[914..916] to)
                  (NP (CD:[917..920] 180) (NN:[920..921] %)))))
            (,:[921..922] ,)
            (S
              (NP-SBJ (NN:[923..924] p))
              (VP (SYM:[925..926] =)
                (NP (CD:[927..933] 0.0186)))))
          (-RRB-:[933..934] -RRB-))))
    (.:[934..935] .)))

;sentence 7 Span:936..1017
;This study shows that grapefruit juice  increases the bioavailable amount of
;EE2.
;[958..974]:substance:"grapefruit juice"
;[1013..1016]:substance:"EE2"
(SENT
  (S
    (NP-SBJ (DT:[936..940] This) (NN:[941..946] study))
    (VP (VBZ:[947..952] shows)
      (SBAR (IN:[953..957] that)
        (S
          (NP-SBJ (NN:[958..968] grapefruit) (NN:[969..974] juice))
          (VP (VBZ:[976..985] increases)
            (NP
              (NP (DT:[986..989] the) (JJ:[990..1002] bioavailable)
                  (NN:[1003..1009] amount))
              (PP (IN:[1010..1012] of)
                (NP (NN:[1013..1016] EE2))))))))
    (.:[1016..1017] .)))

;sentence 8 Span:1018..1113
;A possible explanation may be that  grapefruit juice inhibits the metabolic
;degradation of EE2.
;[1054..1070]:substance:"grapefruit juice"
;[1109..1112]:substance:"EE2"
(SENT
  (S
    (NP-SBJ (DT:[1018..1019] A) (JJ:[1020..1028] possible)
            (NN:[1029..1040] explanation))
    (VP (MD:[1041..1044] may)
      (VP (VB:[1045..1047] be)
        (SBAR-PRD (IN:[1048..1052] that)
          (S
            (NP-SBJ (NN:[1054..1064] grapefruit) (NN:[1065..1070] juice))
            (VP (VBZ:[1071..1079] inhibits)
              (NP
                (NP (DT:[1080..1083] the) (JJ:[1084..1093] metabolic)
                    (NN:[1094..1105] degradation))
                (PP (IN:[1106..1108] of)
                  (NP (NN:[1109..1112] EE2)))))))))
    (.:[1112..1113] .)))

;sentence 9 Span:1114..1273
;Whether the  increased bioavailability of EE2 following grapefruit juice
;administration is of  clinical importance should be investigated in long-term
;studies.
;[1156..1159]:substance:"EE2"
;[1170..1186]:substance:"grapefruit juice"
(SENT
  (S
    (SBAR-NOM-SBJ-1 (IN:[1114..1121] Whether)
      (S
        (NP-SBJ
          (NP (DT:[1122..1125] the) (VBN:[1127..1136] increased)
              (NN:[1137..1152] bioavailability))
          (PP (IN:[1153..1155] of)
            (NP
              (NP (NN:[1156..1159] EE2))
              (PP (VBG:[1160..1169] following)
                (NP
                  (NML (NN:[1170..1180] grapefruit) (NN:[1181..1186] juice))
                  (NN:[1187..1201] administration))))))
        (VP (VBZ:[1202..1204] is)
          (PP-PRD (IN:[1205..1207] of)
            (NP (JJ:[1209..1217] clinical) (NN:[1218..1228] importance))))))
    (VP (MD:[1229..1235] should)
      (VP (VB:[1236..1238] be)
        (VP (VBN:[1239..1251] investigated)
          (NP-1 (-NONE-:[1251..1251] *))
          (PP (IN:[1252..1254] in)
            (NP
              (NML (JJ:[1255..1259] long) (HYPH:[1259..1260] -)
                   (NN:[1260..1264] term))
              (NNS:[1265..1272] studies))))))
    (.:[1272..1273] .)))

;section 10 Span:1277..1295
;Publication Types:
(SEC
  (FRAG (NNP:[1277..1288] Publication) (NNP:[1289..1294] Types)
        (::[1294..1295] :)))

;section 11 Span:1301..1315
;Clinical Trial
(SEC
  (FRAG (NNP:[1301..1309] Clinical) (NNP:[1310..1315] Trial)))

;section 12 Span:1321..1348
;Randomized Controlled Trial
(SEC
  (FRAG (NNP:[1321..1331] Randomized) (NNP:[1332..1342] Controlled)
        (NNP:[1343..1348] Trial)))

;section 13 Span:1352..1396
;PMID: 8631189 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1352..1356] PMID) (::[1356..1357] :) (CD:[1358..1365] 8631189)
        (NN:[1366..1367] -LSB-) (NNP:[1367..1373] PubMed) (::[1374..1375] -)
        (NN:[1376..1383] indexed) (IN:[1384..1387] for)
        (NNP:[1388..1396] MEDLINE-RSB-)))
